Author
Shalini Sharma
Bio: Shalini Sharma is an academic researcher. The author has contributed to research in topics: Insulin resistance & Arteriosclerosis. The author has an hindex of 5, co-authored 23 publications receiving 152 citations.
Papers
More filters
•
22 Jan 2007
TL;DR: In this article, compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.
Abstract: Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.
105 citations
•
13 Mar 2009
TL;DR: In this paper, the use of a compound represented by Formula IA or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing a condition in a mammalian subject is described.
Abstract: Described herein is the use of a compound represented by Formula IA or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing a condition in a mammalian subject, the condition being gout, hyperuricemia, elevated levels of uric acid that do not meet the levels customarily justifying a diagnosis of hyperuricemia, or tumor-lysis syndrome: (see formula IA)
11 citations
•
09 Feb 2004
TL;DR: In this paper, compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.
Abstract: Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.
8 citations
•
30 Apr 2009
TL;DR: In Formula 1, x is 1 or 2: y is 0, 1, 2 or 3; and R1 is selected from the group consisting of hydrogen, alkyl having 1 or two carbon atoms, hy-droxy, alkoxy, chloro, bromo, and amino as discussed by the authors.
Abstract: Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula I. The uric acid-lowering effects of the compounds of this invention are used to treat or prevent a variety of conditions in-cluding gout, hyperuricemia, elevated levels of uric acid that do not meet the levels customarily justifying a diagnosis of hyper-uricemia, renal dysfunction, kidney stones, cardiovascular disease, risk for developing cardiovascular disease, tumor-lysis syn-drome, cognitive impairment, early-onset essential hypertension, and Plasmodium falciparum-induced inflammation. In Formula 1, x is 1 or 2: y is 0, 1, 2 or 3; and R1 is selected from the group consisting of hydrogen, alkyl having 1 or 2 carbon atoms, hy-droxy, alkoxy having 1 or 2 carbon atoms, fluoro. chloro, bromo, and amino. A is phenyl unsubstituted or substituted by one, two or three groups selected from the group consisting of halo, alkyl having 1 or 2 carbon atoms. perfluoromethyL alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring atoms wherein the cycloalky! is unsubstituted or one one two ring carbons are independently mono-substituted by methyl or ethyl; or a 5 or 6 membered heleraromatic ring having 1 or 2 ring heteroatoms selected from N. S and 0 and the heteroaromatic ring is covalently bound to the remainder of the compound by a ring carbon.
7 citations
•
02 Jul 2007
TL;DR: In this article, compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.
Abstract: Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.
5 citations
Cited by
More filters
•
04 Feb 2008
TL;DR: In this article, the authors provide compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, and/or neuronal tissue.
Abstract: In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, and/or neuronal tissue. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRIIB protein and/or an ActRIIB ligand.
125 citations
•
16 Jul 2004TL;DR: In this paper, the authors describe pan-active compounds that are active on PPARs and methods for developing or identifying compounds having a desired selectivity profile, including panactive compounds.
Abstract: Compounds are described that are active on PPARs, including pan-active compounds. Also described are methods for developing or identifying compounds having a desired selectivity profile.
113 citations
•
[...]
20 Dec 2002
TL;DR: Coumpounds, compositions and methods for modulating the activity of nuclear receptors are provided in this paper, in particular, heterocyclic compounds are provided to modulate the activation of liver X receptor (LXR) and orphan nuclear receptors.
Abstract: Coumpounds, compositions and methods for modulating the activity of nuclear receptors are provided In particular, heterocyclic compounds are provided for modulating the activity of nuclear receptors, including liver X receptor (LXR) and orphan nuclear receptors In certain embodiments, the compounds are N-substituted pyridones
109 citations
•
22 Jan 2007
TL;DR: In this article, compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.
Abstract: Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.
105 citations
•
07 Dec 2007TL;DR: In this article, the authors proposed a modulator of the activity of liver X receptors (LXR) and Farnesoid X receptor (FXR), where R00, R200, R400, R500, J11, J21, G1, G21, and Q are defined.
Abstract: Compounds of the invention are disclosed, such as compounds of formulae LX - LXIV, and pharmaceutically acceptable salts, isomers, or prodrugs thereof, which are useful as modulators of the activity of liver X receptors (LXR) and Farnesoid X receptors (FXR), where R00, R200, R400, R500, J11, J21, G1, G21, and Q are defined herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
70 citations